Le Lézard
Classified in: Health, Business
Subject: LIC

Anaeropharma Science Signs Collaborative Research Agreement with Astellas on Creation of Novel Anti-Tumor Drugs Using Bifidobacterium


TOKYO, Sept. 25, 2018 /PRNewswire/ -- Anaeropharma Science Inc. headquartered in Tokyo (hereafter "Anaeropharma") announced on September 25 that Anaeropharma and Astellas Pharma Inc. headquartered in Tokyo (hereafter "Astellas") have concluded a collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes characteristic features of Bifidobacterium longum through Anaeropharma's proprietary platform technology, in situ Delivery and Production System ("i-DPS"). An overview of the contract follows.

(Logo: https://kyodonewsprwire.jp/img/201809198120-O1-E6qt0Z44)

1. A collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes i-DPS technology

Under the terms of the agreement, the two companies shall conduct joint research regarding specific substances in order to create drug candidates for cancer therapy that utilizes Bifidobacterium as a drug delivery carrier. Astellas shall acquire the right of first negotiation regarding the exclusive licensing necessary for commercialization based on the results of this joint research. The agreement shall not constrain any research and development activities of i-DPS conducted by Anaeropharma applying to any molecules other than the above-mentioned specific substances.

2. About i-DPS and its Development Programs

Bifidobacterium is obligatory anaerobe which exists as enteroflora in the human body, and known as nonpathogenic bacteria. Solid cancers have immature vascular constructs and their interstitial tumors are in the state of hypoxia. The company aims to leverage the recombinant Bifidobacterium technology named i-DPS to create a new class of anti-cancer drugs. The technology offers broad potential to be more effective to solid tumors and generates anti-tumor drugs with less risks of adverse events than conventional anti-cancer drugs.

The leading development product using i-DPS technology, APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is under a phase 1 clinical trial in the U.S.

3. About Anaeropharma Science, Inc.

A privately held biopharmaceutical company based in Chiyoda-ku, Tokyo, Japan. Anaeropharma Science was established to pioneer the development of novel therapeutics to target a hypoxic environment in solid cancers based on its proprietary platform technology, i-DPS, using recombinant Bifidobacterium. The company's laboratory is located in the campus of Shinshu University in Matsumoto, Nagano Prefecture. Its CEO is Tetsuya Mishima.

Official website: http://www.anaeropharma.co.jp/

SOURCE Anaeropharma Science, Inc.


These press releases may also interest you

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....

at 10:00
Driving is the leading cause of work-related death each year in the United States, with nearly 40% of deaths on the job occurring on American roads according to the U.S. Bureau of Labor Statistics. A major contributing factor to road deaths each...

at 10:00
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according...

at 10:00
NastLaw LLC announces: If you purchased certain named generic pharmaceutical drugs directly from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019, your rights may be affected by proposed class action settlements.A...

at 09:48
Perspire Sauna Studio, one of the country's largest sauna franchises specializing in full spectrum infrared (IR) and red-light therapy (RLT), is rolling out a new sauna design and member experience through the brand's long-standing partnership with...



News published on and distributed by: